Reneo Pharmaceuticals, Inc. (RPHM)
Chart Events
Performance Outlook
| Previous Close | 12.47 |
| Open | 12.53 |
| Bid | 11.42 x 800 |
| Ask | 11.70 x 800 |
| Day's Range | 11.44 - 12.72 |
| 52 Week Range | 11.44 - 17.18 |
| Volume | 27,845 |
| Avg. Volume | 182,295 |
| Market Cap | 279.876M |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
Fair Value
Related Research
- Daily – Vickers Top Buyers & Sellers for 04/16/2021
- Daily – Vickers Top Buyers & Sellers for 04/15/2021
- Benzinga
The Daily Biotech Pulse: Leadership Transition At Amarin, Vaccine Setback For J&J, FDA Nod For Label Expansion of Roche's Asthma Drug
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs April 12) 180 Life Sciences Corp. (NASDAQ: ATNF) (moved on insider buying) Celcuity Inc. (NASDAQ: CELC) Fortress Biotech, Inc. (NASDAQ: FBIO) Gain Therapeutics, Inc. (NASDAQ: GANX) Medtronic plc (NYSE: MDT) Merit Medical Systems, Inc. (NASDAQ: MMSI) MiMedx Group, Inc. (NASDAQ: MDXG) Down In The Dumps (Biotech Stocks Hitting 52-week Lows April 12) 4D Molecular Therapeutics, Inc. (NASDAQ: FDMT) ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) Achilles Therapeutics plc (NASDAQ: ACHL) (reacted to presentation at the American Association of Cancer Research annual meeting) Acutus Medical, Inc. (NASDAQ: AFIB) Adverum Biotechnologies, Inc. (NASDAQ: ADVM) Adagene Inc. (NASDAQ: ADAG) Aprea Therapeutics, Inc. (NASDAQ: APRE) Assembly Biosciences, Inc. (NASDAQ: ASMB) Axsome Therapeutics, Inc. (NASDAQ: AXSM) Bellerophon Therapeutics, Inc. (NASDAQ: BLPH) Biophytis SA (NASDAQ: BPTS) Bolt Biotherapeutics, Inc. (NASDAQ: BOLT) Calithera Biosciences, Inc. (NASDAQ: CALA) Checkmate Pharmaceuticals, Inc. (NASDAQ: CMPI) (reacted to AACR presentation) Coherus BioSciences, Inc. (NASDAQ: CHRS) Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) ContraFect Corporation (NASAQ: CFRX) Decibel Therapeutics, Inc. (NASDAQ: DBTX) Design Therapeutics, Inc. (NASDAQ: DSGN) Fusion Pharmaceuticals Inc. (NASDAQ: FUSN) Idera Pharmaceuticals, Inc. (NASDAQ: IDRA) Immunocore Holdings plc (NASDAQ: IMCR) IMARA Inc. (NASDAQ: IMRA) Instil Bio, Inc. (NASDAQ: TIL) (moved on AACR presentation) Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) Kronos Bio, Inc. (NASDAQ: KRON) (reacted to preclinical data presented at AACR meeting) Longboard Pharmaceuticals, Inc. (NASDAQ: LBPH) MediciNova, Inc. (NASDAQ: MNOV) Metacrine, Inc. (NASDAQ: MTCR) Millendo Therapeutics, Inc. (NASDAQ: MLND) NeuBase Therapeutics, Inc. (NASDAQ: NBSE) Qualigen Therapeutics, Inc. (NASDAQ: QLGN) (withdrew emergency use authorization application for COVID-19 diagnostic test) Reata Pharmaceuticals, Inc. (NASDAQ: RETA) Reneo Pharmaceuticals, Inc. (NASDAQ: RPHM) (went public Friday) Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) Sarepta Therapeutics, Inc. (NASDAQ: SRPT) Sigilon Therapeutics, Inc. (NASDAQ: SGTX) Soleno Therapeutics, Inc. (NASDAQ: SLNO) Syros Pharmaceuticals, Inc. (NASDAQ: SYRS) Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) VectivBio Holding AG (NASDAQ: VECT) (went public Friday) Y-mAbs Therapeutics, Inc. (NASDAQ: YMAB) (presented clinical data at AACR meeting) Stocks In Focus Amarin Names Insider Karim Mikhail As CEO Amarin Corporation plc (NASDAQ: AMRN) announced that CEO John Thero has informed the board of directors of his plan to retire from the position of CEO effective Aug. 1. He will also step down from the board at that time. The board has appointed Karim Mikhail, Amarin's senior SVP and head of commercial for Europe, to succeed Thero as the company's next president and CEO and as a board member. Thero will continue to provide his guidance and expertise to the company in an advisory capacity through the end of 2021, the company said. The stock was down 2.74% premarket at $5.68. Johnson & Johnson's Vaccine Use Paused By FDA The Food and Drug Administration and the Centers for Disease Control and Prevention are recommending a pause in the use of Johnson & Johnson's (NYSE: JNJ) COVID-19 vaccine due to reports of a rare type of blood clots. The stock was down 2.68% at $157.30 in premarket trading Tuesday. Roche Snags FDA Approval For Self-Injectable, Prefilled Syringe For Asthma Drug Roche Holding AG (OTC: RHHBY) said the U.S. Food and Drug Administration has approved its supplemental Biologics License Application for Xolair, a prefilled syringe for self-injection across all approved U.S. indications. Xolair is the only FDA-approved biologic designed to target and block immunoglobulin E for the treatment of moderate to severe persistent allergic asthma, chronic idiopathic urticaria and nasal polyps. Immunocore Presents Positive Phase 3 Data For Eye Cancer Drug Immunocore presented at the AACR annual meeting with data from a Phase 3 trial comparing tebentafusp with investigator's choice, in first-line metastatic uveal melanoma, showing tebentafusp demonstrated a statistically significant and clinically meaningful improvement in overall survival as a first-line treatment for the condition. Treatment-related adverse events were manageable and consistent with the proposed mechanism. The stock rose 3.57% to $33.37 in after-hours trading. Burning Rock Biotech's Liquid Biopsy Assay Performs Strongly In Midstage Study Burning Rock Biotech Limited (NASDAQ: BNR) announced the publication in Nature Biotechnology of results from a FDA-led Sequencing Quality Control Phase 2 study. The data shows the liquid biopsy assay has achieved strong performance. For samples at a 25ng input, Burning Rock's assay was the most accurate assay, with roughly equivalent sensitivity but superior precision compared to other assays, the company said. Related Link: The Week Ahead In Biotech (April 11-17): Avenue Therapeutics FDA Decision and Conference Presentations In The Spotlight Lilly-Innovent Presents Positive Late-Stage Tyvyt Data In Second-Line Lung Cancer Setting Eli Lilly and Company (NYSE: LLY) and Hong Kong-based partner Innovent Biologics presented at the AACR annual meeting with results of the Phase 3 ORIENT-3 study evaluating Tyvyt versus the chemotherapy medication docetaxel as a second-line treatment for advanced or metastatic squamous non-small cell lung cancer. The presentation shows that Tyvyt demonstrated a statistically significant improvement in overall survival compared to docetaxel, meeting the pre-specified primary endpoint. The median progression-free survival as assessed by investigators was 4.3 months versus 2.79 months, and the confirmed objective response rate was 25.5% versus 2.2%, respectively. Safety was consistent with previous studies of Tyvyt and no new safety signals were identified. Tiziana to Seek Nasdaq Listing For Former Subsidiary Accustem Tiziana Life Sciences PLC (NASDAQ: TLSA) announced that its former subsidiary Accustem Sciences Limited intends to file a listing application with the Nasdaq after completion of the distribution of shares in Accustem to Tiziana shareholders. The Nasdaq listing venue is more appropriate to the nature of Accustem's business in the view of Accustem's board. The stock was trading 0.69% higher at $706.80 premarket Tuesday. Offerings Liquidia Corporation (NASDAQ: LQDA) said it has entered into a common stock purchase agreement with certain institutional, accredited investors for the private placement of 8.626 million shares of common stock at a purchase price of $2.52 per share. The private placement is expected to close Tuesday and yield gross proceeds of approximately $21.7 million. On The Radar Clinical Readouts Affimed N.V. (NASDAQ: AFMD) will present at the AACR annual meeting initial clinical data from an investigator-sponsored Phase 1 study evaluating cord blood-derived natural killercells pre-complexed with Affimed's innate cell engager AFM13. The company's shares reacted positively Friday when the company released a statement elaborating on data from the study. Auris Medical Holding Ltd. (NASDAQ: EARS) is scheduled to provide a business update on its pre-clinical asset AM-301. AM-301 is being evaluated for protection against airborne viruses and allergens. Related Link: Attention Biotech Investors: Mark Your Calendar For April PDUFA Dates See more from BenzingaClick here for options trades from BenzingaThe Week Ahead In Biotech (April 11-17): Avenue Therapeutics FDA Decision and Conference Presentations In The SpotlightThe Daily Biotech Pulse: Negative Regulatory Tidings For Provention Bio, Celcuity Soars On In-licensing Deal, 2 IPOs© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
- InvestorPlace
Biotech Stocks: 14 Things to Know as the VECT Stock IPO and RPHM Stock IPO Begin Trading Today
Biotech stocks are making headlines on Friday as two companies join the public market via initial public offerings (IPOs) today. Source: Shutterstock Let’s dive into the first of the new biotech stocks joining the market today below. Biotech Stocks: VectivBio (NASDAQ:VECT) VectivBio is listing 7.5 million shares of VECT stock on the Nasdaq Exchange at a price of $17 each. It expects to generate $127.5 million in proceeds from the IPO. There’s also a 30-day option for underwriters to purchase an additional 1.125 million shares at the IPO price. The offering is expected to close on Tuesday. VectivBio is a clinical-stage biotechnology company focused on discovering and developing treatments for severe rare conditions with unmet needs. Investors appear receptive to the IPO with more than 705,000 shares trading as of this writing. It’s also worth pointing out that the price of VECT stock has jumped nearly 21.5% to above $20 per share Friday afternoon. Now let’s take a look at the second biotech company joining the public market today.InvestorPlace - Stock Market News, Stock Advice & Trading Tips Biotech Stocks: Reneo Pharmaceuticals (NASDAQ:RPHM) Reneo Pharmaceuticals is listing 6.25 million shares of RPHM stock on the Nasdaq Exchange for $15 per share. It’s expecting the offering to bring in gross proceeds of $93.8 million. The IPO also includes a 30-day option for underwriters to purchase an additional 937,500 of RPHM stock at the IPO price. The company is also expecting the offering to close on Tuesday. Reneo Pharmaceuticals is a biotechnology company focusing on the development of therapies for patients suffering from rare genetic mitochondrial diseases. As of this writing, more than 1.22 million shares of RPHM stock have traded. However, the stock has been dipping lower since going public with shares down 1.7%, bring it below its IPO price. These two biotech stocks aren’t the only recent IPOs worth talking about. Several other companies have been going public lately through the traditional means, or are making plans to do so. Among them are TuSimple, Coinbase (NASDAQ:COIN), and AppLovin. Investors can learn more about these companies’ IPO plans at the links below. More IPO News TuSimple IPO: When Does TuSimple Go Public? What Is the TSP Stock IPO Price Range? Coinbase IPO: The Price Target One Analyst Thinks COIN Stock Will Hit AppLovin IPO News: 9 Things for Potential APP Stock Investors to Know On the date of publication, William White did not have (either directly or indirectly) any positions in the securities mentioned in this article. More From InvestorPlace Why Everyone Is Investing in 5G All WRONG It doesn’t matter if you have $500 in savings or $5 million. Do this now. Top Stock Picker Reveals His Next Potential 500% Winner Stock Prodigy Who Found NIO at $2… Says Buy THIS Now The post Biotech Stocks: 14 Things to Know as the VECT Stock IPO and RPHM Stock IPO Begin Trading Today appeared first on InvestorPlace.
- GlobeNewswire
Reneo Pharmaceuticals Announces Pricing of Initial Public Offering
SAN DIEGO, April 08, 2021 (GLOBE NEWSWIRE) -- Reneo Pharmaceuticals, Inc., a clinical stage pharmaceutical company focused on the development and commercialization of therapies for patients with rare, genetic, mitochondrial diseases, today announced the pricing of its initial public offering of 6,250,000 shares of its common stock at a public offering price of $15.00 per share, for total gross proceeds of approximately $93.8 million, before deducting underwriting discounts and commissions and offering expenses. All of the shares are being offered by Reneo. The shares are expected to begin trading on the Nasdaq Global Market on April 9, 2021 under the symbol “RPHM.” In addition, Reneo has granted the underwriters a 30-day option to purchase up to an additional 937,500 shares of common stock at the public offering price less underwriting discounts and commissions. The offering is expected to close on April 13, 2021, subject to satisfaction of customary closing conditions. Jefferies, SVB Leerink and Piper Sandler are acting as joint book-running managers for the offering. A registration statement relating to these securities has been filed with the Securities and Exchange Commission and became effective on April 8, 2021. The offering is being made only by means of a prospectus. Copies of the final prospectus relating to the offering may be obtained, when available, from: Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, 2nd Floor, New York, NY 10022, by telephone at (877) 821-7388 or by e-mail at prospectus_department@jefferies.com; SVB Leerink LLC, Attention: Syndicate Department, One Federal Street, 37th Floor, Boston, MA, 02110, by telephone at (800) 808-7525, ext. 6105 or by e-mail at syndicate@svbleerink.com; or Piper Sandler & Co., Attention: Prospectus Department, 800 Nicollet Mall, J12S03, Minneapolis, MN 55402, by telephone at (800) 747-3924 or by e-mail at prospectus@psc.com. This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of, these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. About Reneo PharmaceuticalsReneo is a clinical stage pharmaceutical company focused on the development and commercialization of therapies for patients with rare genetic mitochondrial diseases, which are often associated with the inability of mitochondria to produce adenosine triphosphate (ATP). Reneo is developing REN001 to modulate genes critical to metabolism and generation of ATP, which is the primary source of energy for cellular processes. REN001 has been shown to increase transcription of genes involved in mitochondrial function and increase fatty acid oxidation, and may increase production of new mitochondria. Contacts: Joyce AllaireManaging DirectorLifeSci Advisors, LLCjallaire@lifesciadvisors.com Vinny JindalChief Financial OfficerReneo Pharmaceuticals, Inc.investors@reneopharma.com
